Project Grant R01AR086156
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Pennsylvania a $546,145 Project Grant effective May 1, 2026, through March 31, 2031, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research project, titled "Molecular Mechanisms of Telomere Function in Muscle Cells," will deliver fundamental scientific research and discovery outputs focused on...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1.85 million Project Grant to the University of California, San Diego to conduct basic research on the role of lysine acetylation in skeletal muscle contractile function. Awarded on September 15, 2025, with completion targeted for August 31, 2028, this research project will produce scientific findings, peer-reviewed publications, and mechanistic data advancing understanding of...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Johns Hopkins University a $543,417 Project Grant effective June 1, 2026 through May 31, 2031, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research initiative focuses on promoting functional neuromuscular regeneration following chronic volumetric muscle loss (VML) in aged mice. The project will deliver three primary...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Nebraska Board of Regents $198,263 under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) on September 5, 2025, with a completion date of August 31, 2027. This project grant supports research investigating the role of Mitsugumin 53 (MG53) in preventing disuse-induced muscle atrophy, a condition that accelerates age-related muscle...
- Federal Grant Award Summary The University of Wisconsin–Madison received a $116,005 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective May 1, 2026 through April 30, 2028. This award supports research investigating molecular mechanisms of neutrophil reverse migration in wound healing contexts. The project deliverables include identification of key neutrophil subpopulations...
- Federal Project Grant Award Summary The University of Georgia Research Foundation, Inc., received a $614,390 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective May 1, 2026, through April 30, 2031. This award funds fundamental research into the molecular mechanisms of human myogenesis, with a specific focus on elucidating the role of the CHAMP1...
- Federal Grant Award Summary The National Institute on Aging awarded University of Wisconsin-Madison a $698,690 Project Grant on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct molecular and cellular research on age-related skeletal muscle dysfunction. The five-year project, concluding January 31, 2031, will investigate the differential effects of aging on slow versus fast muscle fiber types to elucidate mechanisms underlying sarcopenia (age-related muscle loss),...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $554,797 project grant to The University of Kentucky Research Foundation, effective September 1, 2025, through May 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This project grant funds basic science research to define the rate of myonuclear turnover in adult skeletal muscle, identify mechanisms by which myonuclei are...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $100,228 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective November 16, 2026, with a completion date of May 31, 2029. The award funds basic science research investigating mechanosensation in muscle-resident mesenchymal stromal cells, specifically...
- Federal Grant Award Summary The University of Wisconsin – Madison received a $500,000 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with performance through July 31, 2027. The project delivers research and development services focused on developing and testing a novel immune inhibitory transgene for delivery to vascular composite allografts during normothermic preservation. The primary objective...
The University of Wisconsin–Madison received a $553,640 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective June 1, 2026, through April 30, 2031. This research project investigates JMJD3, an H3K27 demethylase enzyme, as a critical regulator of muscle stem cell (MuSC) function and regeneration following tissue injury. The primary deliverable is fundamental scientific research defining the epigenetic and transcriptional mechanisms by which JMJD3 enables muscle stem cells to modulate inflammatory responses and initiate tissue repair through communication with immune cells. The research will produce peer-reviewed publications, mechanistic data on JMJD3-dependent gene regulation, and preclinical findings that advance understanding of how epigenetic enzymes orchestrate the regenerative niche environment. Specifically, the project aims to elucidate how JMJD3 removes repressive histone marks at immunomodulatory genes, permitting muscle stem cells to both respond to regenerative signals and actively broadcast cues that calibrate immune cell behavior. The research outputs will contribute to the broader NIAMS portfolio supporting basic science investigations into musculoskeletal disease pathogenesis and may inform future therapeutic approaches for conditions involving impaired muscle regeneration and dysfunctional immune-stem cell communication.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $553.6k | 6/1/26 |